Skupin-Mrugalska P
No ORCID on file
· 2 papers in corpus
· active 2021-2024
Top journals
Frequent coauthors
- Bryl R 1
- Garbuzenko O 1
- Hatefi A 1
- Kempisty B 1
- Kulus M 1
- Minko T 1
- Nowicki A 1
- Piotrowska-Kempisty H 1
- Paul Mozdziak 1
- Pieńkowski W 1
2024
BackgroundOlaparib is a PARP inhibitor inducing synthetic lethality in tumors with deficient homologous recombination (HRD) caused by BRCA1/2 mutations. The FDA has approved monotherapy for first-line platinum-sensitive, recurrent high-grad…
2021
Despite the increasing development of medicine, ovarian cancer is still a high-risk, metastatic disease that is often diagnosed at a late stage. In addition, difficulties in its treatment are associated with high resistance to chemotherapy …